

April 30, 2026

<p>To</p> <p>The Corporate Relations Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001</p> <p>Code: 540222</p>	<p>To</p> <p>The Listing Department National Stock Exchange of India Ltd., Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051</p> <p>Code: LAURUSLABS</p>
--	--

Dear Sir / Madam,

Sub: Investors / Analysts Presentation

Please find enclosed the presentation to the Investors / Analysts on the Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2026, for the Investors / Analysts call scheduled on April 30, 2026 at 05.00 p.m. (IST), which was already intimated on April 09, 2026.

The presentation is also being uploaded on the website of the Company i.e., www.lauruslabs.com.

This is for your information and records.

Thanking you,

Yours sincerely,
For **Laurus Labs Limited**

VENKATESWAR
REDDY GOGIREDDY

Digitally signed by VENKATESWAR
REDDY GOGIREDDY
Date: 2026.04.30 15:21:00 +05'30'

G. Venkateswar Reddy
Company Secretary & Compliance Officer

Encl: A/a

Registered Office

Laurus Labs Limited

Laurus Enclave, Plot Office 01, E, Bonangi Village,
Parawada Mandal, Anakapalli District - 531021, Andhra Pradesh, India.

T +91 891 682 1101, 1102, **F** +91 891 682 1103

E info@lauruslabs.com, **W** lauruslabs.com

Corporate Office

Plot No. 103, Road No 1, Jubilee Hills,
Hyderabad, Telangana - 500 033, India.

T +91 40 6659 4333

F +91 40 6659 4320

CIN : L24239AP2005PLC047518

FY 2026 Financial Results

30/04/2026



Safe Harbor Statement

This presentation contains statements that constitute “forward looking statements” including and without limitation, statements relating to the implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these forward looking statements represent our judgment and future expectations concerning the development of our business, such statements reflect various assumptions concerning future developments and a number of risks, uncertainties and other important factors that could cause actual developments and results to differ materially from our expectations.

These factors include, but not limited to: 1) Change in the General market and macro-economic conditions for key global markets where we operate, 2) Governmental and regulatory trends, 3) Allocations of funds by the Governments in our key global markets, 4) Successful implementation of our strategy, R&D efforts, growth & expansion plans and technological changes, 5) Movements in currency exchange and interest rates, 6) Increase in the competitive pressures and Technological developments, 7) Changes in the financial conditions of third parties dealing with us, 8) Changes in laws and regulations that apply to our customers, suppliers and Pharmaceutical industry.

Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results, performance or achievements of Laurus Labs Limited may vary materially from those described in the relevant forward-looking statements

The information contained in this presentation is current, and if not stated otherwise, made as of the date of this presentation. The Company undertakes no obligation to update or revise any information in this presentation as a result of new information, future events or otherwise.

This presentation is strictly confidential and may not be copied or disseminated, reproduced, re-circulated, re-distributed, published or advertised in any media, website or otherwise, in whole or in part, and in any manner or for any purpose without written approval from Laurus Labs Limited. Any unauthorized use, disclosure or public dissemination of information contained herein is prohibited.

This presentation is for information purpose only and is not a prospectus, a statement in lieu of a prospectus, an offering circular, an advertisement or an offer document under the Companies Act, 2013, as amended, or the rules made thereunder, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, or any other applicable law in India.

By accessing this presentation, you accept that this disclaimer and any claims arising out of the use of the information from this presentation shall be governed by the laws of India and only the courts in Telangana, India, and no other courts, shall have jurisdiction over the same.

1


Corporate Overview

FY 2026



Laurus @20 years of Transformation & Value creation

Unique story of High quality growth



Amongst few companies in India which has earned >25% Revenue CAGR and >30% Profits CAGR

Biggest Wealth creator in Indian Healthcare space ^

Laurus Labs: **11.6x**

BSE 500 index: 3.3x


Pharma index India: BSE Health: 3.0x / Nifty Pharma: 2.1x

MSCI India SmallCap: 3.0x

Total Market cap >30% CAGR since 2016 till now

Total dividend payout of ₹631 crore till now

From Single API product supplier to Global Pharma company



Profit year, ^ since Laurus IPO (Dec 2016) and ₹1000 Cr + Revenues category, based on Price as on 24 April 2026



Case study for Scale and Execution

	2016	2026
Employees	2,227	8,126
Capacity	1830kL	>8200kL/ 12bn units
# Clients served	>190 (+1 Big pharma)	>275 (+7 Big pharma)
# Sites	3	15
# Shareholder base	56,724^	3,00,789

FY 2026 – Accelerated performance backed by Leading commercial offering

Full Year 2026 in numbers

4Q 2026



Strong Execution and Strengthening Future growth

ARV leadership



- Continued capacity leadership
- Successful OTIF track record
- TLD demand rebalancing
- Focus entirely on maintenance capex

Commercial momentum



- Late-stage/Commercial supplies of multiple complex NCE APIs
- Expanding multi-site manufacturing capacity
- ₹3000 Cr Capex for ongoing growth projects
- 532 acres land allotment; >\$600mn Capex commitment
- Successful regulatory audits

Technological advancement



- Build end to end capability to synthesize peptides from Lab scale to commercial scale
- Several projects across scale executed using Flow chemistry, Bio-catalysis technologies
- Gene Therapy/ADC investments; PD labs operational and building cGMP facility

Strong Financials



- Strong growth in Revenues and Profits
- Expanded profitability; at Gross and EBITDA levels
- Strategically deployed Free cash to high yielding business
- Sharp improvement in net debt leverage and Healthy balance sheet

Upholding ESG



- Included in S&P Sustainability Yearbook 2025-consecutive
- Investment in Green energy projects
- Highest Cybersecurity performance score 938/950 by UpGuard #1 industry rank


Business Division: Strong diversified growth, underpin by integrated model

Strong diversified performance

Divisions	CAGR % FY 20-26	FY 26 Growth	FY26 Revenue mix
CDMO ¹	+33%	+36%	31%
Affordable medicines (GENERICS) ²	+12%	+18%	69%

ARV de-risking continues

Transformation continues with consistent rise in CDMO revenue share and continued decline in ARV share



¹ includes Small Molecules & Bio business performance, ² includes FDF and API business performance, * Oncology, Cardiovascular, Diabetes, Gastro and Asthma

Strengthening Large-scale manufacturing network & capabilities to support customers



● Site under expansion or construction

¹ Through our Associate company ImmunoACT, [^] Capacity proposed in Phase 1

Growth CAPEX progress across portfolio

>85% Growth CAPEX in diversified portfolio

11 On-going growth projects
(7 API + 2 FDF + 1 Fermentation + 1 Gene Therapy/ADC)



90% Invested into Medium & large scale manufacturing assets

16% Capex/Sales in FY26 in-line


>1.0x Asset turns projected in medium-term in line with 5 year Long term average

CAPEX ₹4300 Cr¹ FY22-26,
15% of Sales

ATR
progress
(FY22-26)



■ API/CDMO ■ Drug Product ■ Ramp-up ■ Operational ■ On-going CAPEX



¹ Cumulative Net addition including CWIP, Land, ETP and plant maintenance till March 2026

New 532 acre Vizag site to significantly enhance our global commercial scale, technology and growth; Capex beginning towards end-FY27, part of an 8-year, >\$600 mn investment plan

Exemplary Quality track record - Commitment to “One Quality for all Markets”

132

Quality audit completed in FY26: Regulatory # 4 & Customer # 128

54

Successful Inspections by major Regulators (US FDA, WHO, EU EMA, and Japan PMDA)

1400+

Quality audits & Inspection by Global Customers, Regulators since inception



Australian Government
Department of Health
Therapeutic Goods Administration



FDA Last US FDA inspection

Key Facilities	Key Regulatory Certifications	Date	# audits (since inception)	EIR Status
Kilo Lab – R&D	USFDA, TGA, KFDA, PMDA, ANVISA - Brazil	2024	5	✓
Unit 1	USFDA, TGA, MHRA, WHO-Geneva, PMDA, ANVISA	2024	7	✓
Unit 2	USFDA, WHO-Geneva, EMA	2023	5	✓
Unit 3	USFDA, WHO-Geneva, JAZMP-Slovenia, ANVISA	2024	5	✓
Unit 4	WHO-Geneva, USFDA	2025	2	✓
Unit 5	USFDA	2022	1	✓
Unit 6	USFDA	2018	1	✓

Advancing ESG agenda, consistently recognized by Global agencies



Named in S&P Global Sustainability Yearbook consecutively in 2025



Consecutive “BBB” ratings in 2022-26

S&P Global ESG Score

81/100

Data Availability: ■ Very High

Last updated: November 05, 2025

Improved Score by +10pp over last year



Member of PSCI as Supplier Partner



Near-term emission reduction targets under validation - 2025



Multiple EHS best practice awards received



Joined the United Nations Global Compact (UNGC) in Jan 2026



GPW certified for Sixth consecutive Year

Significant updates

- Advanced foam tender installed across manufacturing sites
- Focus on decarbonizing products
- Investment in Green energy projects (Solar + Wind)
- Increased use of green technologies and intelligent equipment
- Targets* to reduce Scope 1+2 emission by >40% & Scope 3 by >50% by FY31 vs. FY25

* submitted to SBTi for validation in Dec 2025

2

Financial Overview

FY 2026



FY 2026: Strong performance

FY26 Financial Summary

₹ Crore]	FY26	FY25	Y-o-Y
Revenues	6,813	5,554	23%
Gross Margins	60.4%	55.4%	5.0%
EBITDA¹	1,826	1,115	64%
% to Revenues	26.8%	20.1%	6.7%
Net Profit	889	358	148%
% to Revenues	13.0%	6.4%	6.6%
EPS (₹)	16.4	6.6	148%
Operating Cash flow	1,624	602	170%
Capex	1,070	659	62%
Net Debt-to-EBITDA	1.3x	2.3x	-44%
ROCE	17.7%	9.7%	+8.0%

Comments

- Revenues : ₹ 6,813 Cr, increased 23% driven by continued strong growth across both CDMO and Affordable Medicine (Generics) division
- Gross Margins : 60.4%, increased by 500 bps on better divisional mix
- R & D spends reported at ₹ 282 Cr (4.1% of Revenues)
- EBITDA : ₹ 1,826 Cr, increased by 64%
- EBITDA Margins : 26.8%, increased 670 bps, due to product mix and overall strong revenues driving positive operating leverage
- Net Profits : ₹ 889 Cr, increased 148%
- Strong OCF due to higher EBITDA and improved Net Working capital
- Net Debt to EBITDA reduction largely inline
- Better operating leverage driving ROCE while CAPEX momentum continued

¹ EBITDA includes one-time gain of ₹ 59 Cr related to Sale of Land parcel in FY25, translating to ₹ 0.9 positive EPS impact (net of tax)


FY 2026: Robust CDMO execution, supported by growth in Affordable Medicines

FY26 Divisional Revenue Performance

[₹ Crore]	FY26	FY25	Y-o-Y
CDMO	2,080	1,534	36%
Small molecules	1,896	1,374	38%
Bio	184	160	15%
Affordable Medicines (Generics)	4,733	4,020	18%
API	2,746	2,438	13%
FDF	1,987	1,582	26%
Total Revenues	6,813	5,554	23%
ARV Revenues*	2,807	2,559	10%

* Includes API and Formulation (FDF) combined revenues

FY26 Divisional Mix



FY 2026: Financial Position

FY26 Balance sheet

[₹ Crore]	FY26	FY25	Y-o-Y
Net Fixed assets (incl. CWIP)	4,879	4,316	+563
Goodwill and Intangibles	265	266	-1
Net Working Capital (A+B-C)	3,245	2,985	+260
A. Inventories	2,342	1,937	
B. Receivables	2,155	2,007	
C. Payables	1,252	959	
Other assets & liabilities *	-805	-501	-304
Cash and Cash Equivalents	113	100	+13
Equity	5,300	4,473	+827
Debt (current + non-current)	2,397	2,693	-296
Total Net Assets	7,697	7,166	+531

Increase in net fixed assets

Increase mainly in property, plant and equipment due to

- Investments in ADC/Gene Therapy PD lab & cGMP manufacturing facility in Hyderabad site
- Drug Product line expansion, Commercial peptide capacity, Intermediate/API mfg. blocks (Human & Animal health) at Vizag site

Increase in net working capital

- Increase mainly due to a increase in inventories and accounts receivables

Increase in Other assets & liabilities

- Increase mainly in customer advances

Decrease in Net Debt

- Decrease mainly due to improved operational efficiency and cashflows. Long term debt remained stable

* Includes Current and non-current assets/liabilities (Provisions, Lease liabilities, Advance from customers, Deferred income tax, accrued corporate tax, etc)

4Q FY26: Achieved highest Revenue and Operating profits

4Q FY26 Financial Summary

[₹ Crore]	3Q FY26	4Q FY26	4Q FY25	Y-o-Y	Q-o-Q
Revenues	1,778	1,812	1,720	5%	2%
Gross Margins	60.9%	61.4%	54.5%	+6.9%	+0.5%
EBITDA¹	485	523	477	10%	8%
% to Revenues	27.3%	28.9%	27.7%	+1.2%	+1.6%
Net Profit	252	279	234	+19%	+11%
% to Revenues	14.2%	15.4%	13.6%	+1.8%	+1.2%
EPS (₹)	4.7	5.2	4.3	+21%	+13%

Comments

- Revenues : ₹ 1,812 Cr, increased 5% primarily driven by robust CDMO growth supported by steady Affordable medicine business (led by APIs)
- Gross Margins : 61.4%, increased by 690 bps on better divisional mix
- R & D spends reported at ₹ 76 Cr (4.2% of Revenues)
- EBITDA : ₹ 523 Cr, increased by 10% Y/Y
- EBITDA Margins : 28.9%, increased 120 bps Y/Y, due to favorable product mix and improving operational leverage
- Net Profits : ₹ 279 Cr, increased 19% Y/Y
- Interim Dividend of ₹ 1.20/- per share

¹ EBITDA includes one-time gain of ₹ 59 Cr related to Sale of Land parcel in 4QFY25, translating to ₹ 0.9 positive EPS impact (net of tax)


4Q FY26: Driven by healthy CDMO performance

4Q FY26 Divisional Revenue Performance

[₹ Crore]	3Q FY26	4Q FY26	4Q FY25	Y-o-Y	Q-o-Q
CDMO	451	589	490	20%	31%
Small molecules	408	524	461	14%	28%
Bio	43	65	29	124%	51%
Affordable Medicines (Generics)	1,327	1,223	1,230	-1%	-8%
API	720	772	686	13%	7%
FDF	607	451	544	-17%	-26%
Total Revenues	1,778	1,812	1,720	5%	2%
ARV Revenues*	744	683	803	-15%	-8%


* Includes API and Formulation (FDF) combined revenues

4Q FY26 Divisional Mix




Quarterly Performance Summary: Sustained growth momentum


Revenues




RoCE (ttm EBIT/Capital Employed)



EBITDA & Gross Profit Margins




Net Leverage (Net Debt/ ttm EBITDA)




Financial Highlights FY 2020-26


Revenues




EBITDA & Gross Profit Margins



RoCE



Net Profit



3


Business Review & Strategy

FY 2026



CDMO – Small molecules: Strong demand and operational execution

Revenue Growth




Comments

- Strong growth benefitted from late stage pipeline and commercial NCE API supplies
- Sustained clinical and commercial contracting across technologies and sites driving good growth outlook
- Advancing on commercial peptides manufacturing capability/capacities to enable customer future needs
- Expanding customer base in Animal Health and Crop sciences
- Continued focus on new modalities with key partners and fully integrated projects
- Crossed 8200kL of reactor volumes in FY26. Continuing CAPEX in large-scale API & fermentation capacity at Vizag site

CDMO – Small molecules: Expanding pipeline and diversified portfolio

Expanding Pipeline & Solid foundation to drive future manufacturing growth


Active Projects



- Small molecules pipeline continue to expand, based on trust, capabilities, scale and delivery
- Diversified portfolio by technology, indications and customer type
- Majority of commercial revenues from products early in their commercial journey

Bio – Healthy demand visibility, robust pipeline building continues

Revenue Growth




Comments

- Healthy growth through revenue diversification. Continued pipeline progress on larger Global accounts
- Acceleration in Product development and launch activities
- Improving mix of higher value products and customers within CDMO
- Expanding enzymatic technology application across small molecule clinical and commercial API projects
- Large-scale Fermentation manufacturing site (Vizag) build up on track

Affordable Medicines – Strong execution, Demand led capacity creation continues

Revenue Growth



Global FDF filings	US	EU	Canada	ROW
Approved	37*	19	16	59
Pending	12	3	7	9
Total	49	22	23	68


* Includes 15 Tentative approvals in US

Comments

- Strong full year, led by both FDF and API. Sustained volume led ARV leadership and maximized US/EU opportunity on select molecules
- Maintained consistent deliveries despite global supply chain challenges
- Ongoing capacity creation, new launch ramp-up/integrated CMO and expanding footprint across DM/EM to support FY27
- **Filings update: DMF filings - Cumulatively, 92 filed till date.** Developed market FDF filings - 7 dossiers filed and 6 approvals received in FY26. Cumulatively, 94 product filed till date
- Increased FDF capacity by 20% in FY26. Additional packaging line being implemented at Unit 2 with full commercial production line starting from June 2026

ARV – Leadership and Committed to saving lives globally

ARV business de-risking continues



ARV: Antiretroviral

Industry environment

- Overall stable market environment, supported by adequate funding by multi-lateral agencies
- Dolutegravir use to remain steady over the next couple of years
- Long-acting injectable adoption challenges in adherence and retention

Performance and Outlook

- Demand driven growth in line with expectation
- Sustained ARV leadership and return to stabilized margins in FY26. Continue to service 1/3rd of HIV population globally
- Maintain focus on optimal capacity, portfolio breadth and operational excellence amidst ongoing supply chain disruption

Advanced Biologics – Investments in Gene / ADC platform building continues

Gene Therapy /ADC cGMP facility in Hyderabad



- Broke ground for >65000 sq.ft site in Q1 . Focus on comprehensive PD , bioconjugation services and ADCs
- Gram to Multi-kilogram scale to support Phase 1-3 clinical and commercial supplies
- Investment expected > ₹200 Cr
- Facility commissioning and qualification by mid 2027


R&D lab already started operations in Dec 2025



- Process development lab started in Dec 2025 (technologies at site: Bioconjugation, Plasmids & AAV gene therapy services)
- Incorporates industry-leading equipment and technologies
- Emerging ADC field and evolving market demand
- Investments in ADC platform company Aarvik Therapeutics to help advance integrated ADC services


Cell therapy – Accelerate NexCAR adoption and operating leverage

NexCAR19™
Actalycabtagene autoleucel



- Healthy clinical profile driving strong volume growth
- Partnership with Cipla to launch NexCAR-19 in Africa

New CAR-T GMP facility, Nerul



- Commissioned in March 2026
- +2,500 annual treatment capacity (3x increase)

Forward focus

- Accelerate NexCar19 clinical adoption
- Expansion of product portfolio
- Global partnerships & Licensing pathways

Other material updates

- BCMA Ph-1 trials ongoing for r/r Multiple Myeloma
- Strengthening leadership team
- Continued investment in Product, Process, People for commercial scale-up

Earnings call details

Laurus Labs Results Conference Call to be held on Thursday, 30 April 2026 at 5:00 PM IST

Dial – In – Details

Universal Dial-In	+91 22 6280 1384
India Local access Number	+91 22 7115 8285
Singapore	+800 1012045
Hong Kong	+800 964448
USA	+1 866 746 2133
UK	+0808 101 1573

**Click below to Express Join with
Diamond Pass**

[Click here to register](#)

Additional Information

Laurus Labs is a research-driven pharmaceutical and biotechnology company committed to improving global health. It holds a leadership position in developing and manufacturing select Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDF) across anti-retroviral, oncology, cardiovascular, and gastro therapeutics. With strong backward integration and stringent quality standards, Laurus has built a solid reputation for high-quality, innovative solutions. The company offers end-to-end Contract Development and Manufacturing Organization (CDMO) services, supporting innovators from early-stage development to commercial production. Laurus employs over 8,126 people, including 3,134+ scientists, and operates 15 facilities approved by global regulators like the USFDA, WHO, EMA, and more. Its “Smart and Green” chemistry approach drives sustainable manufacturing and operational excellence.

Laurus Labs generated ₹6,813 crore in revenue in FY2026 and is listed on the BSE and NSE. The company is a certified Great Place to Work and holds a “BBB” MSCI ESG rating, reflecting its commitment to transparency, integrity, and ESG principles. It is widely recognized for upholding environmental stewardship and ethical business practices. Expanding beyond small molecules, Laurus is enhancing its capabilities in biotechnology, large molecules, cell, and gene therapies. Its diversified offerings span human and animal health APIs, intermediates, crop science, and specialty ingredients for nutrition and cosmetics. Guided by the principle “Chemistry for Better Living,” Laurus remains dedicated to advancing science for better global health outcomes. Corporate Identification No: L24239AP2005PLC047518.

Investor relations

Vivek Kumar

T: +914066594366

E: investorrelations@lauruslabs.com

E: vivek.k@lauruslabs.com

For more information

Please visit our website www.lauruslabs.com



Please consider the environment before printing this Presentation